Drug search by name

Diltiazem Intravenous and Gengraf Capsules

Determining the interaction of Diltiazem Intravenous and Gengraf Capsules and the possibility of their joint administration.

Check result:

Diltiazem Intravenous <> Gengraf Capsules

Relevance: 07.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using dilTIAZem together with cycloSPORINE can be harmful to the kidneys. Symptoms of kidney damage include swelling, weight gain, feeling short of breath, drowsiness, confusion, mood changes, increased thirst, loss of appetite, nausea and vomiting, pain in your lower back, and urinating more or less than usual or not at all. Contact your doctor if you also experience diarrhea, muscle pain or weakness, dizziness, fatigue, or headache. If you take both medications together, tell your doctor if you have any of these symptoms. You may need a dose adjustment or special tests to safely use these medications together. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Diltiazem may inhibit the CYP450 3A4 hepatic metabolism of cyclosporine. Trough and steady state levels, and the risk of nephrotoxicity may be increased.

MANAGEMENT: Cyclosporine levels and renal function should be monitored, and dosage should be adjusted as needed and appropriate during therapy. Other calcium channel blockers that have lesser effects on cyclosporine metabolism may be considered as alternatives (e.g., amlodipine, isradipine, nifedipine, nitrendipine).

References

Oppenheimer F, Alcaraz A, Manalich M, et al "Influence of the calcium blocker diltiazem on the prevention of acute renal failure after renal transplantation." Transplant Proc 24 (1992): 50-1
"Product Information. Sandimmune (cyclosporine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Brockmoller J, Neumayer HH, Wagner K, et al "Pharmacokinetic interaction between cyclosporin and diltiazem." Eur J Clin Pharmacol 38 (1990): 237-42
Puig JM, Lloveras J, Oliveras A, et al "Usefulness of diltiazem in reducing the incidence of acute tubular necrosis in Euro-Collins-preserved cadaveric renal grafts." Transplant Proc 23 (1991): 2368-9
Kunzendorf U, Walz G, Brockmoeller J, et al "Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients." Transplantation 52 (1991): 280-4
Pochet JM, Pirson Y "Cyclosporin-diltiazem interaction." Lancet 1 (1986): 979
Sketris IS, Methot ME, Nicol D, Belitsky, Knox MG "Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients." Ann Pharmacother 28 (1994): 1227-31
Yee GC, McGuire TR "Pharmacokinetic drug interactions with cyclosporin (part II)." Clin Pharmacokinet 19 (1990): 400-15
Wahlberg J, Hanas E, Bergstrom C, et al "Diltiazem treatment with reduced dose of cyclosporine in renal transplant recipients." Transplant Proc 24 (1992): 311-2
Macdonald P, Keogh A, Connell J, Harvison A, Richens D, Spratt P "Diltiazem co-administration reduces cyclosporine toxicity after heart transplantation: a prospective randomised study." Transplant Proc 24 (1992): 2259-62
Grino JM, Sabate I, Castelao AM, Alsina J "Influence of diltiazem on cyclosporin clearance." Lancet 1 (1986): 1387
Neumayer HH, Wagner K "Diltiazem and economic use of cyclosporin." Lancet 2 (1986): 523
Foradori A, Mezzano S, Videla C, Pefaur J, Elberg A "Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazole in stable adult kidney transplants." Transplant Proc 30 (1998): 1685-7
Jacobs U, Klein B, Klehr HU "Cumulative side effects of cyclosporine and ca antagonists: hypergalactinemia, mastadenoma, and gynecomastia." Transplant Proc 26 (1994): 3122
Alcaraz A, Oppenheimer F, Talbot-Wright R, et al "Effect of diltiazem in the prevention of acute tubular necrosis, acute rejection, and cyclosporine levels." Transplant Proc 23 (1991): 2383-4
Sabate I, Grino JM, Castelao AM, et al "Cyclosporin-diltiazem interaction: comparison of cyclosporin levels measured with two monoclonal antibodies." Transplant Proc 21 (1989): 1460-1
Morris RG, Jones TE "Diltiazem disposition and metabolism in recipients of renal transplants." Therapeutic Drug Monitoring 20 (1998): 365-70
Cockburn IT, Krupp P "An appraisal of drug interactions with sandimmun." Transplant Proc 21 (1989): 3845-50

Diltiazem Intravenous

Generic Name: diltiazem

Brand name: Cardizem, Cartia XT, Dilacor XR, Dilt-CD, Diltia XT, Dilt-XR, Diltzac, Matzim LA, Taztia XT, Tiazac, Cardizem CD, Tiazac, Cardizem LA, Tiazac Extended Release Capsules

Synonyms: Diltiazem

What is Diltiazem Intravenous?

Gengraf Capsules

Generic Name: cyclosporine

Brand name: Gengraf, Neoral, Sandimmune, Sandimmune

Synonyms: Gengraf (Capsules, Modified), Gengraf

What is Gengraf Capsules?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions